Loading…

D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment

The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the pheno...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy 2022-03, Vol.30 (3), p.1188-1200
Main Authors: Yang, Quanjun, Hao, Juan, Chi, Mengyi, Wang, Yaxian, Li, Jie, Huang, Jinlu, Zhang, Jianping, Zhang, Mengqi, Lu, Jin, Zhou, Shumin, Yuan, Ting, Shen, Zan, Zheng, Shuier, Guo, Cheng
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113
cites cdi_FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113
container_end_page 1200
container_issue 3
container_start_page 1188
container_title Molecular therapy
container_volume 30
creator Yang, Quanjun
Hao, Juan
Chi, Mengyi
Wang, Yaxian
Li, Jie
Huang, Jinlu
Zhang, Jianping
Zhang, Mengqi
Lu, Jin
Zhou, Shumin
Yuan, Ting
Shen, Zan
Zheng, Shuier
Guo, Cheng
description The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness. [Display omitted] Guo et al. reveal the immunosuppressive effect of D2HG and explore the phenotypic characteristics of modified CAR-T cells through knock-out and over-expression of D2HGDH. D2HGDH over-expression in CAR-T cells improves the killing effect against cancer cells through the potential of metabolic adaptability in an immunosuppressive environment.
doi_str_mv 10.1016/j.ymthe.2022.01.007
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8899596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001622000077</els_id><sourcerecordid>2618909344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113</originalsourceid><addsrcrecordid>eNp9UU2LFDEQDaK46-ovECRHL90m6e-DwjKrO8KCIOs5pJNqp4ZOMibphvXXm3HWQS-eUqFevVevHiGvOSs54-27fflg0w5KwYQoGS8Z656QS96IpmBM1E_PNW8vyIsY97nizdA-JxdVk8FdM1ySnzdie3uzLSwYVAkMPf6pVkmNfsZoKbidchoizVJUuYRFWqwPVOmEKybMHT_RzfXX4p5qmOdI0WUcRWsX5-NyOASIEVegFnXw4FYM3llw6SV5Nqk5wqvH94p8-_TxfrMt7r7cft5c3xW6boZUdIoxpsdKiZYpPYlmHIypjW51xfkErDPdxKqm5VMnNIhuNJVgbc-V6Y0aOa-uyIcT72EZs02dpYOa5SGgVeFBeoXy347DnfzuV9n3w5DvlQnePhIE_2OBmKTFePSqHPglStHyfmBDVdcZWp2g2WqMAaazDGfymJrcy9-pyWNqknGZg8hTb_7e8DzzJ6YMeH8CQL7TihBk1Ag5FoMBdJLG438FfgEfj6ym</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618909344</pqid></control><display><type>article</type><title>D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment</title><source>PubMed Central</source><creator>Yang, Quanjun ; Hao, Juan ; Chi, Mengyi ; Wang, Yaxian ; Li, Jie ; Huang, Jinlu ; Zhang, Jianping ; Zhang, Mengqi ; Lu, Jin ; Zhou, Shumin ; Yuan, Ting ; Shen, Zan ; Zheng, Shuier ; Guo, Cheng</creator><creatorcontrib>Yang, Quanjun ; Hao, Juan ; Chi, Mengyi ; Wang, Yaxian ; Li, Jie ; Huang, Jinlu ; Zhang, Jianping ; Zhang, Mengqi ; Lu, Jin ; Zhou, Shumin ; Yuan, Ting ; Shen, Zan ; Zheng, Shuier ; Guo, Cheng</creatorcontrib><description>The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness. [Display omitted] Guo et al. reveal the immunosuppressive effect of D2HG and explore the phenotypic characteristics of modified CAR-T cells through knock-out and over-expression of D2HGDH. D2HGDH over-expression in CAR-T cells improves the killing effect against cancer cells through the potential of metabolic adaptability in an immunosuppressive environment.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1016/j.ymthe.2022.01.007</identifier><identifier>PMID: 35007759</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alcohol Oxidoreductases - metabolism ; Animals ; Cell Line, Tumor ; Cell Proliferation ; chimeric antigen receptor ; Cytokines - metabolism ; D-2-hydroxyglutarate ; D2HGDH ; Glutarates - metabolism ; Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Mice ; Neoplasms - therapy ; oncometabolites ; Original ; T-Lymphocytes - metabolism ; Tumor Microenvironment</subject><ispartof>Molecular therapy, 2022-03, Vol.30 (3), p.1188-1200</ispartof><rights>2022 The Author(s)</rights><rights>Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><rights>2022 The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113</citedby><cites>FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899596/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899596/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35007759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Quanjun</creatorcontrib><creatorcontrib>Hao, Juan</creatorcontrib><creatorcontrib>Chi, Mengyi</creatorcontrib><creatorcontrib>Wang, Yaxian</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Huang, Jinlu</creatorcontrib><creatorcontrib>Zhang, Jianping</creatorcontrib><creatorcontrib>Zhang, Mengqi</creatorcontrib><creatorcontrib>Lu, Jin</creatorcontrib><creatorcontrib>Zhou, Shumin</creatorcontrib><creatorcontrib>Yuan, Ting</creatorcontrib><creatorcontrib>Shen, Zan</creatorcontrib><creatorcontrib>Zheng, Shuier</creatorcontrib><creatorcontrib>Guo, Cheng</creatorcontrib><title>D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness. [Display omitted] Guo et al. reveal the immunosuppressive effect of D2HG and explore the phenotypic characteristics of modified CAR-T cells through knock-out and over-expression of D2HGDH. D2HGDH over-expression in CAR-T cells improves the killing effect against cancer cells through the potential of metabolic adaptability in an immunosuppressive environment.</description><subject>Alcohol Oxidoreductases - metabolism</subject><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>chimeric antigen receptor</subject><subject>Cytokines - metabolism</subject><subject>D-2-hydroxyglutarate</subject><subject>D2HGDH</subject><subject>Glutarates - metabolism</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive</subject><subject>Mice</subject><subject>Neoplasms - therapy</subject><subject>oncometabolites</subject><subject>Original</subject><subject>T-Lymphocytes - metabolism</subject><subject>Tumor Microenvironment</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UU2LFDEQDaK46-ovECRHL90m6e-DwjKrO8KCIOs5pJNqp4ZOMibphvXXm3HWQS-eUqFevVevHiGvOSs54-27fflg0w5KwYQoGS8Z656QS96IpmBM1E_PNW8vyIsY97nizdA-JxdVk8FdM1ySnzdie3uzLSwYVAkMPf6pVkmNfsZoKbidchoizVJUuYRFWqwPVOmEKybMHT_RzfXX4p5qmOdI0WUcRWsX5-NyOASIEVegFnXw4FYM3llw6SV5Nqk5wqvH94p8-_TxfrMt7r7cft5c3xW6boZUdIoxpsdKiZYpPYlmHIypjW51xfkErDPdxKqm5VMnNIhuNJVgbc-V6Y0aOa-uyIcT72EZs02dpYOa5SGgVeFBeoXy347DnfzuV9n3w5DvlQnePhIE_2OBmKTFePSqHPglStHyfmBDVdcZWp2g2WqMAaazDGfymJrcy9-pyWNqknGZg8hTb_7e8DzzJ6YMeH8CQL7TihBk1Ag5FoMBdJLG438FfgEfj6ym</recordid><startdate>20220302</startdate><enddate>20220302</enddate><creator>Yang, Quanjun</creator><creator>Hao, Juan</creator><creator>Chi, Mengyi</creator><creator>Wang, Yaxian</creator><creator>Li, Jie</creator><creator>Huang, Jinlu</creator><creator>Zhang, Jianping</creator><creator>Zhang, Mengqi</creator><creator>Lu, Jin</creator><creator>Zhou, Shumin</creator><creator>Yuan, Ting</creator><creator>Shen, Zan</creator><creator>Zheng, Shuier</creator><creator>Guo, Cheng</creator><general>Elsevier Inc</general><general>American Society of Gene &amp; Cell Therapy</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220302</creationdate><title>D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment</title><author>Yang, Quanjun ; Hao, Juan ; Chi, Mengyi ; Wang, Yaxian ; Li, Jie ; Huang, Jinlu ; Zhang, Jianping ; Zhang, Mengqi ; Lu, Jin ; Zhou, Shumin ; Yuan, Ting ; Shen, Zan ; Zheng, Shuier ; Guo, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alcohol Oxidoreductases - metabolism</topic><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>chimeric antigen receptor</topic><topic>Cytokines - metabolism</topic><topic>D-2-hydroxyglutarate</topic><topic>D2HGDH</topic><topic>Glutarates - metabolism</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive</topic><topic>Mice</topic><topic>Neoplasms - therapy</topic><topic>oncometabolites</topic><topic>Original</topic><topic>T-Lymphocytes - metabolism</topic><topic>Tumor Microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Quanjun</creatorcontrib><creatorcontrib>Hao, Juan</creatorcontrib><creatorcontrib>Chi, Mengyi</creatorcontrib><creatorcontrib>Wang, Yaxian</creatorcontrib><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Huang, Jinlu</creatorcontrib><creatorcontrib>Zhang, Jianping</creatorcontrib><creatorcontrib>Zhang, Mengqi</creatorcontrib><creatorcontrib>Lu, Jin</creatorcontrib><creatorcontrib>Zhou, Shumin</creatorcontrib><creatorcontrib>Yuan, Ting</creatorcontrib><creatorcontrib>Shen, Zan</creatorcontrib><creatorcontrib>Zheng, Shuier</creatorcontrib><creatorcontrib>Guo, Cheng</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Quanjun</au><au>Hao, Juan</au><au>Chi, Mengyi</au><au>Wang, Yaxian</au><au>Li, Jie</au><au>Huang, Jinlu</au><au>Zhang, Jianping</au><au>Zhang, Mengqi</au><au>Lu, Jin</au><au>Zhou, Shumin</au><au>Yuan, Ting</au><au>Shen, Zan</au><au>Zheng, Shuier</au><au>Guo, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2022-03-02</date><risdate>2022</risdate><volume>30</volume><issue>3</issue><spage>1188</spage><epage>1200</epage><pages>1188-1200</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>The effect of immunotherapy is limited by oncometabolite D-2-hydroxyglutarate (D2HG). D2HGDH is an inducible enzyme that converts D2HG into the endogenous metabolite 2-oxoglutarate. We aimed to evaluate the impairment of CD8 T lymphocyte function in the high-D2HG environment and to explore the phenotypic features and anti-tumor effect of D2HGDH-modified CAR-T cells. D2HG treatment inhibited the expansion of human CD8 T lymphocytes and CAR-T cells, increased their glucose uptake, suppressed effector cytokine production, and decreased the central memory cell proportion. D2HGDH-modified CAR-T cells displayed distinct phenotypes, as D2HGDH knock-out (KO) CAR-T cells exhibited a significant decrease in central memory cell differentiation and intracellular cytokine production, while D2HGDH over-expression (OE) CAR-T cells showed predominant killing efficacy against NALM6 cancer cells in high-D2HG medium. In vivo xenograft experiments confirmed that D2HGDH-OE CAR-T cells decreased serum D2HG and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1. Our findings demonstrated that the immunosuppressive effect of D2HG and distinct phenotype of D2HGDH modified CAR-T cells. D2HGDH-OE CAR-T cells can take advantage of the catabolism of D2HG to foster T cell expansion, function, and anti-tumor effectiveness. [Display omitted] Guo et al. reveal the immunosuppressive effect of D2HG and explore the phenotypic characteristics of modified CAR-T cells through knock-out and over-expression of D2HGDH. D2HGDH over-expression in CAR-T cells improves the killing effect against cancer cells through the potential of metabolic adaptability in an immunosuppressive environment.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35007759</pmid><doi>10.1016/j.ymthe.2022.01.007</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1525-0016
ispartof Molecular therapy, 2022-03, Vol.30 (3), p.1188-1200
issn 1525-0016
1525-0024
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8899596
source PubMed Central
subjects Alcohol Oxidoreductases - metabolism
Animals
Cell Line, Tumor
Cell Proliferation
chimeric antigen receptor
Cytokines - metabolism
D-2-hydroxyglutarate
D2HGDH
Glutarates - metabolism
Humans
Immunotherapy
Immunotherapy, Adoptive
Mice
Neoplasms - therapy
oncometabolites
Original
T-Lymphocytes - metabolism
Tumor Microenvironment
title D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A15%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=D2HGDH-mediated%20D2HG%20catabolism%20enhances%20the%20anti-tumor%20activities%20of%20CAR-T%20cells%20in%20an%20immunosuppressive%20microenvironment&rft.jtitle=Molecular%20therapy&rft.au=Yang,%20Quanjun&rft.date=2022-03-02&rft.volume=30&rft.issue=3&rft.spage=1188&rft.epage=1200&rft.pages=1188-1200&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1016/j.ymthe.2022.01.007&rft_dat=%3Cproquest_pubme%3E2618909344%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-7a000cb3a260acf25b9dd4dc6c311fe07d7f03561f72ce27bd320681ad8dab113%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2618909344&rft_id=info:pmid/35007759&rfr_iscdi=true